What the Form 8.3 Filings Behind Gooch & Housego's Buyout Tell You

A small British photonics maker agreed in July to be bought for cash by a U.S. private-equity firm, and since that day a stream of oddly titled filings — "Form 8.3" — has been landing on the news wire. For most investors they read as regulatory noise. Read correctly, they are a running ledger of who is betting on the deal, how much they are betting, and whether the market thinks it will actually complete.

Gooch & Housego (LSE: GHH) makes precision optical components — imaging and sighting systems for aerospace and defense, optics for medical devices, and acousto-optic parts that steer laser beams in industrial and semiconductor tooling. On July 16 it agreed to a recommended £345.6 million cash takeover by Arlington Capital Partners, a Washington-based buyout house with over $14 billion of committed capital. Each share is worth 1,234.9 pence including a 4.9p interim dividend, a 41% premium to the closing price the day before the deal was announced.

That condition — "recommended cash acquisition," implemented as a court-sanctioned scheme of arrangement — is what triggers the Form 8.3s. Under the UK Takeover Code, once an offer period starts, any person holding an interest of 1% or more in "relevant securities" of the company must publicly disclose that position and any subsequent dealings. The filings are the market's way of keeping a contested-situation ledger in the open: everyone can see who owns what, and who is changing what, on the way to a vote.

What the recent Form 8.3s show is that merger arbitrageurs have piled in. Sand Grove Capital, a London event-driven fund, disclosed an interest of roughly 10.4% in G&H as of September 8 — about 8.2% held in stock plus another 2.1% in cash-settled derivatives. Qube Research & Technologies, a systematic fund, disclosed a delta position of around 1.5% built almost entirely through cash-settled derivatives rather than physical shares. Arithmetic that exploits a spread, not an opinion about photonics.

The trade is straightforward. A deal is set at a fixed cash price below the intrinsic-growth story, so the stock trades at a discount to that price until completion. Arbitrageurs buy the target, collect the offer price, and keep the difference. The bigger and more aligned their positions, the stronger the signal they expect the deal to close. What confuses a first-time reader — a hedge fund holding a large block in a company it has no interest in running — is exactly the point: these are positions built to be exited on a closing, not held as an investment.

The operating story beneath it, though, is not the usual private-equity rescue. G&H is growing. In the six months to March 31 revenue rose about 9% on an organic constant-currency basis to £81.9 million, aerospace and defense was up a sharp 51.7%, and the order book climbed 16.5% to £167.3 million. The board still chose to sell rather than run the business public, citing the difficulty of funding heavy R&D and M&A from a thinly traded AIM small cap amid tariff and supply-chain uncertainty. The buyer is paying roughly 25.9x adjusted operating profit and about 35x trailing adjusted earnings — a full price for a company with rising defense demand.

Which brings me to the number that carries the real risk: the gap between that 1,234.9p offer and the ~1,205p the stock actually trades at. It is only about 2%. A tight spread is the market saying completion is probable; a wide one is the market pricing real doubt. Here the doubt is regulatory, and photonics with an aerospace-and-defense book is precisely the kind of asset that draws it. The U.S. antitrust waiting period has cleared — Gooch & Housego confirmed on September 1 that the Hart-Scott-Rodino window expired — but the deal still needs UK national security clearance under the National Security and Investment Act, scrutiny designed exactly for foreign buyouts of defense-linked technology, plus approval from shareholders meeting the 75%-of-votes threshold at the scheme meetings. Completion is targeted for the fourth quarter.

If you hold the shares and want the cash, the arb spread is a carry trade with a specific, finite overhang: the deal either closes around the offer price or fails in a way that revisits a much lower standalone valuation. If you do not hold, the Form 8.3s are a tool for every future takeover you read — they tell you a deal is real, who is underwriting its completion, and what the market already believes. The 2% gap is the marginal belief that remains: a photonics company with escalating defense revenue, selling to a U.S. buyer, waiting on a national-security sign-off. That is the one variable not yet priced.